ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months
- 11 September 2020
- journal article
- research article
- Published by Elsevier BV in Thrombosis Research
- Vol. 196, 297-304
- https://doi.org/10.1016/j.thromres.2020.09.001
Abstract
No abstract availableKeywords
Funding Information
- Daiichi Sankyo Europe GmbH
This publication has 19 references indexed in Scilit:
- Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatmentEuropean Respiratory Journal, 2016
- Global Burden of ThrombosisCirculation Research, 2016
- Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentJournal of Thrombosis and Thrombolysis, 2016
- ThrombosisArteriosclerosis, Thrombosis, and Vascular Biology, 2014
- Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: A systematic reviewThrombosis Research, 2014
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismThe New England Journal of Medicine, 2013
- Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort studyBlood, 2011
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patientsJournal of Thrombosis and Haemostasis, 2009
- Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous ThrombosisThe New England Journal of Medicine, 1979
- ANTICOAGULANT DRUGS IN THE TREATMENT OF PULMONARY EMBOLISM: A CONTROLLED TRIALThe Lancet, 1960